Market Research Reports

Cervical Cancer Diagnostic Tests Market (Pap Smear tests, Colposcopy, HPV Testing, Endocervical Curettage (ECC) and Others (Cone Biopsy and Loop Electrosurgical Excision Procedure (LEEP) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020

86pages
Published Date: 2014-08-25
 

Description


Cervical cancer is a medical condition in which cells present in the lining of the cervix – gradually develop into pre-cancerous mass of cells that ultimately turn into cancerous tumors. Two major types of cervical cancers that are typically screened and diagnosed in women include adenocarcinoma and squamous cell carcinoma. At the same time, it has been observed that approximately 90% cases of cervical cancers are squamous cell carcinoma. Virtually, almost all the cases of cervical cancer cases are due to specific types of human papillomavirus and there are more than 100 different types of HPV virus present, of which nearly 40 are sexually transmitted. Among these, about 15 different types HPV viruses are considered as high-risk type or cancer causing. Today, cervical cancer is recognized to be one of the most common types of cancers affecting U.S. women and ranks 14th in frequency. Worldwide, cervical cancer is the third most common cancer among women and the second most frequent cause of cancer-related death, accounting for almost 300,000 deaths annually.

This research report provides a detailed analysis of the global cervical cancer diagnostic tests market and helps in understanding the various driving factors for the growth of the market. The market overview section analyzes market dynamics and trends such as drivers, restraints and opportunities that influence the current nature and future status of the market. The executive summary provides detailed insights about the report and the market in general. It also contains a market snapshot, which provides a glimpse into the present scenario of the global cervical cancer diagnostic tests market. Impact factors such as market attractiveness analysis and Porter’s five forces analysis have also been explained in the market overview section of the report in order to deliver a thorough analysis of the overall competitive scenario of the global cervical cancer diagnostic tests market. 

The global cervical cancer diagnostic tests market is segmented based on types of tests performed for the diagnosis of cancer patients. Based on the test types, the market is segmented into Pap smear tests, HPV testing, colposcopy, endocervical curettage procedure and others, which comprise cone biopsy and Loop Electrosurgical Excision Procedure (LEEP). Market size estimates and forecasts for the period 2012 to 2020 have been provided for each of the segments mentioned above in terms of USD million, considering 2013 as the base year for calculating market forecast and 2012 as the historical year. The CAGR (%) of each market segment for the forecast period 2014 to 2020 has also been provided along with market size estimations.

Geographically, the global cervical cancer diagnostic tests market has been segmented into four major regional markets: North America, Europe, Asia Pacific and Rest of World (RoW). The market size estimations and forecasts for the period 2012 to 2020 have been provided for each of these regions at a segment level, in terms of USD million along with the CAGR for the forecast period 2014 to 2020. This study further offers market recommendations for the global cervical cancer diagnostic tests market. These include factors that may play a critical role in enhancing or boosting the market in the near future, as well as steps that need to be considered to ensure success for manufacturers. 

The report concludes with the company profiles section and includes key information about the major players who are actively participating in this market. The company profiles included in the report are framed in terms of company overview, financial overview, business strategies, recent developments and product portfolio. Key players profiled in this report include Abbott Laboratories, Becton, Dickinson and Company, Hologic, Inc., F. Hoffmann-La Roche Ltd., Quest Diagnostics, Inc., QIAGEN N.V., Femasys, Inc., Zilico Ltd., Guided Therapeutics, Inc., OncoHealth Corp., 

Table of Contents



Chapter 1 Introduction
1.1 Report Description
1.2 Research Methodology
1.3 Market Segmentation

Chapter 2 Executive Summary
2.1 Market Snapshot: Global Cervical Cancer Diagnostic Tests Market
2.2 Global Cervical Cancer Diagnostic Tests Market, by Type of Tests, 2013 (USD Million)
2.3 Comparative Analysis: Global Cervical Cancer Diagnostic Tests Market, by Geography, 2013 & 2020 (Value %)

Chapter 3 Market Overview
3.1 Introduction
3.2 Market Dynamics
      3.2.1 Market Drivers
               3.2.1.1 Rising prevalence rate of cervical cancer expected to boost market growth
               3.2.1.2 High incidence rate of HPV infections likely to drive the growth of the market
               3.2.1.3 Increasing cervical cancer screening awareness programs assisting in accelerating market growth
               3.2.1.4 Breakthrough products and technologies likely to fuel the growth of the market
      3.2.2 Market Restraints
               3.2.2.1 Lack of appropriate primary healthcare infrastructure to impede the growth of the market
               3.2.2.2 Low awareness hinders the growth of the market
      3.2.3 Market Opportunities
               3.2.3.1 Strengthening distribution network in emerging markets
3.3 Porter’s Five Forces Analysis
      3.3.1 Bargaining Power of Suppliers
      3.3.2 Bargaining Power of Buyers
      3.3.3 Threat of New Entrants
      3.3.4 Threat of Substitutes
      3.3.5 Competitive Rivalry
3.4 Market Attractiveness Analysis: Global Cervical Cancer Diagnostic Tests Market, by Geography
3.5 Heat Map Analysis for Cervical Cancer Diagnostic Tests Market, by Key Market Players

Chapter 4 Global Cervical Cancer Diagnostic Tests Market, by Type of Test
4.1 Introduction
      4.1.1 Global Cervical Cancer Diagnostic Tests Market Revenue, by Type of Tests, 2012 – 2020 (USD Million)
4.2 Pap Smear Tests
      4.2.1 Global Pap Smear Tests Market Revenue, 2012 – 2020 (USD Million)
4.3 Colposcopy
      4.3.1 Global Colposcopy Market Revenue, 2012 – 2020 (USD Million)
4.4 HPV Testing
      4.4.1 Global HPV Testing Market Revenue, 2012 – 2020 (USD Million)
4.5 Endocervical Curettage (ECC)
      4.5.1 Global Endocervical Curettage (ECC) Market Revenue, 2012 – 2020 (USD Million)
4.6 Others (Cone biopsy and Loop Electrosurgical Excision Procedure (LEEP))
      4.6.1 Global Other Cervical Cancer Diagnostic Tests Market Revenue, 2012 – 2020 (USD Million)

Chapter 5 Global Cervical Cancer Diagnostics Tests Market, by Geography
5.1 Overview
      5.1.1 Global Cervical Cancer Diagnostic Tests Market Revenue, by Geography, 2012-2020 (USD Million)
5.2 North America
      5.2.1 North America Cervical Cancer Diagnostic Tests Market Revenue, 2012 - 2020 (USD Million)
5.3 Europe
      5.3.1 Europe Cervical Cancer Diagnostic Tests Market Revenue, 2012 - 2020 (USD Million)
5.4 Asia Pacific
      5.4.1 Asia Pacific Cervical Cancer Diagnostic Tests Market Revenue, 2012 - 2020 (USD Million)
5.5 Rest of the World (RoW)
      5.5.1 RoW Cervical Cancer Diagnostic Tests Market Revenue, 2012 - 2020 (USD Million)

Chapter 6 Recommendations
6.1 Success Strategies (Key Focus Areas)
      6.1.1 Gain Accreditation to Ensure Qualification to Participate in National Screening Programs across the Regions
      6.1.2 Target Emerging Markets of Asia Pacific and RoW
      6.1.3 Intensify Promotion and Training Programs for Healthcare Professionals
      6.1.4 Emphasis on Research and Development to come up with Innovative Solutions

Chapter 7 Company Profiles
7.1 Abbott Laboratories
      7.1.1 Company Overview
      7.1.2 Financial Overview
      7.1.3 Product Portfolio
      7.1.4 Business Strategies
      7.1.5 Recent Developments
7.2 Becton, Dickinson and Company
      7.2.1 Company Overview
      7.2.2 Financial Overview
      7.2.3 Product Portfolio
      7.2.4 Business Strategies
      7.2.5 Recent Developments
7.3 Hologic, Inc.
      7.3.1 Company Overview
      7.3.2 Financial Overview
      7.3.3 Product Portfolio
      7.3.4 Business Strategies
      7.3.5 Recent Developments
7.4 F. Hoffmann-La Roche Ltd.
      7.4.1 Company Overview
      7.4.2 Financial Overview
      7.4.3 Product Portfolio
      7.4.4 Business Strategies
      7.4.5 Recent Developments
7.5 Quest Diagnostics, Inc.
      7.5.1 Company Overview
      7.5.2 Financial Overview
      7.5.3 Product Portfolio      
      7.5.4 Business Strategies      
      7.5.5 Recent Developments
7.6 QIAGEN N.V.
      7.6.1 Company Overview
      7.6.2 Financial Overview
      7.6.3 Product Portfolio
      7.6.4 Business Strategies
      7.6.5 Recent Developments
7.7 Femasys, Inc.
      7.7.1 Company Overview
      7.7.2 Financial Overview
      7.7.3 Product Portfolio
      7.7.4 Business Strategies
      7.7.5 Recent Developments
7.8 Zilico Ltd.
      7.8.1 Company Overview
      7.8.2 Financial Overview
      7.8.3 Product Portfolio
      7.8.4 Business Strategies
      7.8.5 Recent Developments
7.9 Guided Therapeutics, Inc.
      7.9.1 Company Overview
      7.9.2 Financial Overview
      7.9.3 Product Portfolio
      7.9.4 Business Strategies
      7.9.5 Recent Developments
7.10 OncoHealth Corp.
       7.10.1 Company Overview
       7.10.2 Financial Overview
       7.10.3 Product Portfolio
       7.10.4 Business Strategies

List of Figures

FIG. 1 Global Cervical Cancer Diagnostic Tests Market Segmentation
FIG. 1 Global Cervical Cancer Diagnostic Tests Market, by Type of Tests, 2013 (USD Million)
FIG. 2 Comparative Analysis: Global Cervical Cancer Diagnostic Tests Market, by Geography, 2013 & 2020 (Value %)
FIG. 3 Cervical Cancer Diagnostic Tests Market, Drivers and Restraints
FIG. 4 Porter’s Five Forces Analysis: Cervical Cancer Diagnostic Tests Market
FIG. 5 Market Attractiveness Analysis: Global Cervical Cancer Diagnostic Tests Market, by Geography
FIG. 6 Heat Map Analysis of Key Market Players for the Cervical Cancer Diagnostic Tests Market
FIG. 7 Global Pap Smear Tests Market Revenue, 2012 – 2020 (USD Million)
FIG. 8 Global Colposcopy Market Revenue, 2012 – 2020 (USD Million)
FIG. 9 Global HPV Testing Market Revenue, 2012 – 2020 (USD Million)
FIG. 10 Global Endocervical Curettage (ECC) Market Revenue, 2012 – 2020 (USD Million)
FIG. 11 Global Other Cervical Cancer Diagnostic Tests Market Revenue, 2012 – 2020 (USD Million)
FIG. 12 North America Cervical Cancer Diagnostic Tests Market Revenue, 2012 - 2020 (USD Million)
FIG. 13 Europe Cervical Cancer Diagnostic Tests Market Revenue, 2012 - 2020 (USD Million)
FIG. 14 Asia Pacific Cervical Cancer Diagnostic Tests Market Revenue, 2012 - 2020 (USD Million)
FIG. 15 RoW Cervical Cancer Diagnostic Tests Market Revenue, 2012 - 2020 (USD Million)
FIG. 16 Abbott Laboratories: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 17 Becton, Dickinson & Company: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 18 Hologic, Inc.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 19 F. Hoffmann-La Roche Ltd.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 20 Quest Diagnostics, Inc.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 21 QIAGEN N.V.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 22 Guided Therapeutics, Inc.: Annual Revenue, 2011 – 2013 (USD Million)

List of Tables

TABLE 1 Market Snapshot: Global Cervical Cancer Diagnostic Tests Market
TABLE 2 Global Cervical Cancer Diagnostic Tests Market Revenue, by Type of Tests, 2012 - 2020 (USD Million)
TABLE 3 Global Cervical Cancer Diagnostic Tests Market Revenue, by Geography, 2012 – 2020 (USD Million)

Enquiry Before Buying


Free Market Analysis


According to the World Health Organization (WHO), cervical cancer is the second most commonly prevalent cancer and the third greatest cause of death in women, with 530,000 new cases discovered each year. Increasing number of HIV-infected individuals and suppressed immune system are the primary factors contributing to the growth of the global cervical cancer diagnostic tests market. Furthermore, increasing incidences of sexual contact with an infected individual or multiple partners, long-term use of contraceptive pills and certain genetic factors have contributed to the growth of the cervical cancer diagnostic tests market. However, recently, the number of deaths related to cervical cancer has decreased marginally due to rising awareness about various cervical cancer diagnostic tests such as Pap smear tests and HPV tests. Hence, increasing awareness about the screening and treatment of cervical cancer is expected to boost the growth of the market in the next few years.

The global cervical cancer diagnostics tests market is segmented by test types into Pap smear tests, colopscopy, HPV testing, endocervical curettage (ECC) procedure and others, which includes cone biopsy and loop electrosurgical excision procedure (LEEP). The HPV testing segment accounted for the largest share i.e., over 45% of the total market in 2013. The segment is expected to lead market growth during the forecast period from 2014 to 2020. Factors that have contributed to the high growth of the segment are increasing rate of HPV infection among individuals across geographies, rising incidences of sexually transmittable infections and increasing incidences of smoking. Additionally, most HPV-infected women develop certain mild abnormalities related to the cervix, which would boost the growth of the HPV testing segment. The Pap smear tests segment is also estimated to grow at a high CAGR of more than 6% during the forecast period from 2014 to 2020. The major driving factors for such remarkable growth of the segment are early detection of glandular cell abnormalities through Pap smear test that can be further treated immediately and increasing need among female population for prognosis as well as diagnosis of cervical cancer. Hence, early monitoring of cervical cancer in women has contributed to the high growth of the Pap smear tests segment. Demand for other tests such as colopscopy, ECC, LEEP is growing at an equivalent rate due to high incidences and prevalence of cervical cancer.

Geographically, North America was the largest market for cervical cancer diagnostic tests in 2013. Factors that have driven the market in North America are increasing prevalence of cervical cancer cases, rapid technological advancements, and growing awareness about malignant effects of cervical cancer among individuals. In addition, various reimbursement policies related to the treatment of cervical cancer would most likely fuel the growth of the market in the next few years. However, Asia Pacific is projected to witness the highest growth rate over the forecast period from 2014 to 2020. The rationale behind such growth has been attributed to fast growing consumer market, favorable government support for improved healthcare infrastructure such as hospitals and clinics, and increasing awareness among the population in the developing regions. Moreover, easy market penetration, tax benefits and low labor costs would trigger the growth of the market in the Asia Pacific region. 

Major players operating in the cervical cancer diagnostic tests market are Abbott Laboratories, Becton, Dickinson and Company, and Hologic, Inc. Other companies include Guided Therapeutics, Femasys, Inc., OncoHealth Corp., Quest Diagnostics, Inc., Roche Diagnostics, QIAGEN, and Zilico Ltd. 

global-cervical-cancer-diagnostic-tests-market

 

To get discount on this report, just click on the button below.

To receive brochure, please click on the button below.

Share This Market Study!  

Upcoming Report

Payment
Copyright @ Transparency Market Research